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Background: Rectal adenocarcinoma (RAC) is a common malignant tumor of the 
digestive tract and survival is highly dependent upon stage of disease at diagnosis. 
Lipidomic strategy can be used to identify potential biomarkers for establishing early 
diagnosis or therapeutic programs for RAC.
Objective: To evaluate the lipoperoxidation biomarkers and lipidomic signature in the 
plasma of patients with RAC (n = 23) and healthy controls (n = 18).
Methods: Lipoperoxidation was evaluated based on malondialdehyde (MDA) and 
F2-isoprostane levels and the lipidomic profile obtained by gas chromatography and 
high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical 
technique.
results: The most abundant ions identified in the RAC patients were those of protonated 
phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphati-
dylcholine (LPC) plasmalogen containing palmitoleic acid [LPC (P-16:1)], with highest 
variable importance projection score, showed a tendency to be lower in the cancer 
patients. A reduction of n − 3 polyunsaturated fatty acids was observed in the plasma 
of these patients. MDA levels were higher in patients with advanced cancer (stages III/
IV) than in the early stages groups and the healthy group (p < 0.05). No differences in 
F2-isoprostane levels were observed among these groups.
conclusion: This study shows that the reduction in plasma levels of LPC plasmalogens 
associated with an increase in MDA levels may indicate increased oxidative stress in 
these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signa-
ture for RAC.
Keywords: lipidomic, rectal adenocarcinoma, biomarkers, lipoperoxidation, mass spectrometry
inTrODUcTiOn
Colorectal cancer (CRC) is the third commonest malignant tumor worldwide. Countries with the 
highest incidence rates are Australia, New Zealand, Canada, the United States, and parts of Europe 
(1). In Brazil, colon and rectal cancers are among the five most diagnosed cancers and are the third 
highest cause of cancer-related deaths (2, 3). Rectal cancer is a commonly frequent type of CRC and 
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rectal adenocarcinoma (RAC) is the primary histological type of 
rectal cancer, associated with considerable mortality and morbid-
ity. The overall 5-year survival rate is described as 66.5% (4).
Important cellular functions, such as signal transduction, post-
translational modifications, homeostasis, adhesion, migration, 
apoptosis, and neurotransmission are regulated by phospholipids 
(PLs) (5, 6). These molecules are subject to extensive modification 
in cancer, often with marked alterations in the phosphatidylcho-
line (PC) and phosphatidylethanolamine (PE) metabolism due 
to changes in the activity of degradative enzymes, including 
phospholipase A (7, 8) and anabolic enzymes, especially fatty acid 
synthase, stearoyl-CoA desaturase (SCD) and choline kinase α (9, 
10). Both phospholipase and fatty acid synthase are essential for 
tumor progression and have been identified as potential cancer 
treatment targets (11, 12).
Understanding the occurrence of alterations in plasma meta-
bolic profiles and lipid peroxidation associated with tumor onset 
and progression could lead to better diagnostic tests and could 
uncover new approaches to prevent or even treat CRC. Decreased 
serum levels of unsaturated free fatty acids, C16:1, C18:2, C20:4, 
and C22:6, have been proposed as diagnostic indicators of early 
stages CRC (13). Also, the risk of CRC is increased with elevations 
in serum n −  3 polyunsaturated fatty acids (PUFA) and n −  6 
PUFA (14) and with higher levels of plasma saturated fatty acids 
(SFAs) in plasma PLs, in particular palmitic acid (15). It has been 
reported that the shift from lipid uptake to de novo lipogenesis 
in cancer cells leads to increased membrane lipid saturation and 
higher levels of saturated and monounsaturated PLs, thus render-
ing the cancer cells more protected against the oxidative damage 
by reducing lipid peroxidation (16). However, inhibition of fatty 
acid desaturation following ablation of SCD causes oxidative 
stress, cell cycle inhibition, and apoptosis in cancer cells (17).
Most of the research groups investigating lipidomic profile in 
CRC to elucidate the changes in lipid metabolism have assessed 
the tissue (18–22) and exosomes (23). Biofluid-based detection 
strategies (urine and peripheral blood and its components) are 
an attractive approach for screening, mainly due to their offer 
of non-invasive access to large quantities of samples and ease 
of acquisition. Molecular analyses of early stages rectal cancer-
related plasma represent an attractive choice for the discovery 
and validation of diagnostic biomarkers.
In this study, lipoperoxidation biomarkers [malondialdehyde 
(MDA) and F2-isoprostane] and lipid signatures obtained by gas 
chromatography (GC) and high-resolution mass spectrometry 
(ESI-qToF-MS) followed by multivariate data analysis, including 
principal component analysis (PCA) and (orthogonal) partial 
least squared discriminant analysis [(O)PLS-DA] were applied 
for the rapid investigation of potential diagnostic biomarkers in 
the plasma of RAC patients.
eXPeriMenT
Participants and samples
Plasma samples were obtained from 18 healthy volunteers and 
23 RAC patients stratified into three groups [stage 0, stages I/II, 
and stages III/IV according to the TNM classification system 
of the American Joint Committee on Cancers (AJCC) (24)]. 
The ethics committee of the São Francisco University (CAAE: 
51356315.5.0000.5514) and the Faculty of Medical Sciences of 
the State University of Campinas (CAAE: 08287012.0.0000.5404) 
approved the project. Samples and clinical information on the 
RAC patients were obtained from the Gastrocentro Colorectal 
Cancer Medical Outpatient Facility of the Faculty of Medical 
Sciences of the University of Campinas (UNICAMP) in the 
period 2013 and 2014. All patients over 18 years old with RAC 
diagnosed by histopathology were included in the study. Data 
were collected considering the follow information: age, sex, BMI, 
race, smoker, diagnosis, date of diagnosis (date of biopsy), TNM 
stage, type of surgical treatment, neo/adjuvant treatment, recur-
rence, death, and date of death. The samples were taken prior 
to the patients’ being submitted to surgical procedures, chemical 
therapy, and/or radiotherapy. Clinical examination coupled with 
hemato-biochemical analysis was used to screen healthy controls. 
Informed consent was acquired from participants prior to blood 
collection. The same protocol was used in the collection of plasma 
samples from patients and controls. From each subject, 4 ml of 
whole blood was collected into a tube containing potassium-
EDTA. The plasma was promptly separated and stored at −80°C 
for posterior analysis.
lipid extraction
Lipids were extracted from the plasma (0.8 ml) by the procedure 
of Folch et al. (25) with 5.0 ml of chloroform–methanol (2:1) and 
0.5 ml aqueous solution of 0.1 N NaCl. The lower lipid phase was 
collected, separated into two fractions for subsequent analyses, 
and dried under nitrogen.
lipid classes analysis by electrospray 
ionization Time-of-Flight Mass 
spectrometry (esi-qToF-Ms)
The lipid extracts were diluted in 300 µl of methanol:chloroform 
(2:1) and 100  µl of this solution were re-diluted in 400  µl of 
acetonitrile:chloroform (3:1). Then 1 µl was injected into an LC 
(Agilent 1290) injector of an LC-MS system using no column and 
with a flow of 0.5 ml min−1 of acetonitrile:H2O (1:1). The mass 
spectrometry experiments were performed on a 6550 iFunnel 
q-ToF (Agilent Technologies) coupled with a Dual Agilent Jet 
Stream ESI source (Dual-AJS-ESI). The positive ion mode was 
used for the collection of the mass spectra, applying the following 
conditions: Gas temp. at 290°C, Drying Gas flow at 11 l min−1, 
Nebulizer at 45 psi, Sheath gas temp. at 350°C, Sheath gas flow 12 l 
min−1, VCap 3000, Nozzle voltage 320 V, Fragmenter 100 V, and 
OCT 1 RFV pp 750 V. Agilent Mass Hunter Qualitative Analysis 
software version B.07.00 was used to acquire and process the data. 
The ESI(+)-MS data were exported in CSV files and statistical 
analyses were performed using MetaboAnalyst 2.0.
Fatty acid analysis by gc
The dry extract of total lipids was subjected to derivatization 
before GC analysis. The extracts were converted into fatty acid 
methyl esters using BF3 methanol (26) and analyzed by GC using 
a Chrompack chromatographer (model CP 9001; Chrom Tech, 
TaBle 1 | Demographic data and major clinical characteristics of rectal 
adenocarcinoma (RAC) patients and healthy volunteers.
rac patients healthy volunteers
N 23 18
Sex (M/F) 10:13 10:8
Age (years) 56.6 ± 11.0 55.9 ± 11.9
Race (%)
White 20 (87) 16 (89)
Black 2 (8.7) 2 (11)
Mulatto 1 (4.3) 0
Yellowa 0 0
BMI (kg/m2) 27.5 ± 4.6 25.3 ± 5.1
Smoker (%) –
Yes 4 (17.4) –
No 8 (34.8) –
Ex 5 (21.7) –
No information 6 (26.1) –
Stages (%) –
0 4 (17.4) –
I and II 9 (39.1) –
III and IV 10 (43.5) –
aBrazilian census category of Chinese or Japanese descent.
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Inc.) with a flame ionization detector and a CP-Sil 88 capillary 
column (Chrompak, WCOT Fused Silica) as previously reported 
(27). Fatty acid (FA) identification was made by comparing 
retention times with authentic standards (Sigma) injected under 
the same conditions. FA composition, represented as a percent-
age of total FA, was calculated using area of the chromatogram 
(Software N2000, G-Chrom).
lipoperoxidation Biomarkers
Plasma level of MDA was measured according to the method of 
Ohkawa et al. (28). MDA level was determined by thiobarbituric 
acid reactive substances based on the reaction between MDA 
and thiobarbituric acid (TBA). 250 µl of plasma were mixed with 
25  µl of 4% butylated hydroxytoluene in methanol, 1  ml 12% 
trichloroacetic acid, 1 ml of 0.73% TBA, and 750 µl of 0.1 mol/l 
Tris–HCl buffer containing 0.1 mmol/l EDTA pH 7.4. The reac-
tion yields a pink MDA-TBA adduct, which was measured by 
the spectrophotometer at 532 nm. The method was standardized 
with 1,1,3,3-tetramethoxypropane (malondialdehyde bis dime-
thyl acetal) and MDA concentration was calculated as nmol/ml.
Free 8-isoprostane (8-epi-PGF2) was measured by using 
an enzyme immunoassay kit (8-isoprostane EIA Kit, Cayman 
Chemical Co., Ann Arbor, MI, USA). The plate was incubated 
for 90 min at room temperature, the absorbance read at 412 nm, 
and 8-isoprostane concentration was calculated as pg/ml.
statistical and Multivariate Data analysis
Comparative statistical analysis was conducted to compare the 
two experimental groups. The Tukey test was applied to the means 
and standard deviations of FA composition and lipoperoxidation 
biomarkers, adopting a significance level of p < 0.05 (5%). Data 
assessment used InStat GraphPad 2.0 software, and the graphs 
were elaborated using OriginLab Origin 8.1 software. To enable 
the assessment of lipid classes, Agilent Mass Hunter Qualitative 
Analysis B.07.00 software was used for data acquisition and con-
trol. Exporting files in CSV was carried out for the ESI (+)-MS. 
For the statistical analysis, each molecular feature (ion) was nor-
malized by sum, unsupervised segregation was evaluated using 
statistical web platform Metaboanalyst 2.0. PCA was performed 
using pareto and the results were used to show the lipids that 
most strongly influence the discrimination between groups. To 
enhance data discrimination, the data were also analyzed using 
the (orthogonal) partial least squared discriminant analysis [(O)
PLS-DA] method. Biomarkers were selected according to their 
variable importance in projection (VIP) values. In addition, an 
independent t-test (p ≤ 0.05) was used to evaluate whether dif-
ferent biomarker candidates were statistically significant between 
groups. The differences of FA composition between groups were 
analyzed by one-way ANOVA, followed by the Tukey test and 
p < 0.05 was considered to be statistically significant.
resUlTs
Patient characteristics
A total of 23 patients with RAC and 18 healthy volunteers were 
included in our study. RAC patients included 4 patients with stage 
0 (carcinoma in situ) (17.4%), 9 (39.1%) with early stages (TNM 
staging I/II), and 10 (43.5%) with advanced stages (TNM staging 
III/IV), between 24 and 91  years old. Table  1 summarizes the 
major characteristics of all subjects.
Profile analysis of lipids in Plasma rac 
Patients vs healthy Volunteers
Substantial differences in the lipid profiles were observed in the 
mass spectra of the two groups (Figure  1). To evaluate these 
differences, the data were integrated and co-analyzed using 
unsupervised PCA (Figure S1 in Supplementary Material), 
supervised PLS-DA (Figure 2) and OPLS-DA methods (Figure 
S2 in Supplementary Material). Significant differences in the lipid 
profile were found between RAC patients and healthy subjects, 
with a satisfactory separation of the groups due to contrasting 
concentrations of constituents (Figure 2).
The index values of the variable importance in projection 
(VIP) from PLS-DA were used to measure the importance of 
each individual metabolite (Figure  3). A total of 120 variables 
were initially obtained and 15 ions (m/z) were highlighted by 
PLS-DA as important lipids to differentiate RAC patients from 
healthy volunteers. Nine of those ions were identified as shown 
in Table 2. Some of the ions had their identification confirmed 
by their collision-induced dissociation displayed in their MS/MS 
spectra (Table  2). Ions that could not be evaluated by MS/MS 
were identified with the SimLipid software (PREMIER Biosoft 
International, CA, USA).
Top 15 variables (ions with their m/z) that significantly 
contributed to the discrimination between groups were selected, 
resulting in a 20 VIP value cut-off. In the RAC group, ions of 
m/z 734 and 756 identified as PC or PE; and ions of m/z 792, 820 
identified as PC plasmalogen (PCP) or 1-alkyl PC (PCO) were 
up-regulated, while lisophosphatidylcholine (LPC) metabolites 
(m/z 496 and 524) and three LPC plasmalogens (m/z 478, 506 
FigUre 1 | Representative (+) ESI-MS (q-ToF) mass spectra of plasma from (a) a healthy volunteer and (B) a rectal adenocarcinoma patient. (B) Representation of 
the molecular structure (C24H48NO6P) m/z 478 identified as lisophosphatidylcholine [LPC (P-16:1)].
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and 504) were downregulated compared with healthy subjects. 
LPC plasmalogen of m/z 478 (LPC P-16:1) was the most relevant 
for predicting the response variable.
Table 3 sets out the results for the plasma FAs of the healthy 
volunteers and RAC patients in the different cancer stages. The 
main FAs found in all groups were the SFA followed by the n − 6 
PUFAs and the MUFAs. No significant differences were observed 
in total MUFA and n − 6 PUFA amounts between the 0, I/II, and 
III/IV cancer stages, except for 16:1 n − 7 (p = 0.0455) and 20:4 
n − 6 (p = 0.0472) which were reduced in the I/II cancer stages. 
Reductions were also observed in n − 3 PUFA, docosapentaenoic 
(C22:5 n − 3) (p = 0.0268) and docosahexaenoic (C22:6 n − 3) 
(p = 0.0086) acids in patients at the I/II cancer stages and doc-
osapentaenoic (C22:5 n − 3) (p = 0.0330) acid was reduced in the 
III/IV cancer stages. The plasma of patients at stage 0 (carcinoma 
in situ) showed no alterations in FAs composition. As for the sum 
of the FAs classes (SFA, MUFA, and PUFA), there were no statisti-
cal differences among the groups evaluated.
lipid Peroxidation Determination
The plasma levels of MDA (nmol/mL) and of F2-isoprostane 
(pg/mL) of healthy volunteers and the three groups separated by 
the staging are set out in Figures 4A,B, respectively. The plasma 
levels of MDA in the III/IV cancer stages were higher than the 
values observed in the healthy volunteers and in the stage 0 
group (p < 0.05). No differences in MDA levels were observed in 
patients in the early stages (stages 0 and I/II) compared to healthy 
volunteers (Figure  4A). As regards the F2-isoprostane levels, 
there were no statistical differences among the groups evaluated 
(Figure 4B).
DiscUssiOn
Our results show a significant difference in the lipid profile 
between RAC and healthy subjects. PC/PE and PCP were 
upregulated while those of LPC metabolites with SFAs (16:0 and 
18:0) as well as unsaturated plasmalogens (16:1, 18:1, and 18:2) 
were significantly lower compared with healthy subjects. Also, a 
relative reduction of n − 3 PUFA, already observed in the early 
stage of cancer, and an increase of MDA, a biomarker of oxidative 
stress-induced lipid peroxidation, were observed in the plasma of 
these patients. The increases in MDA levels associated with high 
levels of plasma PCPs are a confirmation of the increased levels 
of oxidative stress.
FigUre 2 | (a) PLS-DA scores plot of healthy volunteers (red) and rectal adenocarcinoma patients (green). 36.5 and 19.2% are the scores of the component 1 and 
2, respectively. (B) Loadings plot for components 1 and 2. (c) Cross validation showing the performance measures (prediction accuracy, R2, and Q2). *best values of 
Q2 (0.97). (D) The permutation test statistics (p < 5e−4). PLS score (T-score) explains Y and maximizes the relation between X and Y.
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Plasmalogens are a unique class of glycerophospholipids con-
taining a fatty alcohol linked by a vinyl-ether moiety at the sn − 1 
position of the glycerol backbone (29). It has been suggested that 
plasmalogens act as molecular scavengers (29), protecting cells 
and lipids against oxidative stress (30, 31), as their vinyl-ether 
bond is highly sensitive to oxidative attack compared to its ester 
counterparts. In vitro studies have indicated that plasmalogens 
are capable of reducing the oxidation of cell membrane PUFA and 
cholesterol (32, 33) and have also been correlated with the reduc-
tion in the levels of several oncogenic signaling lipids involved in 
the regulation of cell survival, cancer aggressiveness, and tumor 
growth (34). By contrast, LPC plasmalogens were decreasing in 
RAC patients; this may occur due to increased actions of lyso-
PC acyltransferases (LPCAT). The exacerbated lipid anabolic 
metabolism in tumor cells is reflected in elevated activity and 
expression of several lipogenic enzymes. The LPCAT1, which 
converts LPC into PCs, is overexpressed in several cancers and 
is associated with colon cancer growth (21, 22) showed that 
LPCAT4 was overexpressed in CRC and contributes to PC 
(16:0/16:1) accumulation via the enhanced re-acylation of LPC.
Also, an abnormal choline-containing compounds metabo-
lism have been identified and associated with oncogenesis and 
tumor progression (35). Choline kinase-α (Chk-α) activity, an 
enzyme in the Kennedy pathway that phosphorylates free choline 
to PC, and PC levels were increased in colon cancer and adenoma 
tissue (36).
The existence of LPC P16:1 was, however, reported here for 
the first time in the plasma of patients with RAC. The presence 
of a plasmalogen in primary and metastatic CRC cell lines (37) 
and in exosomes secreted by the CRC cell line (23) has been 
TaBle 2 | Main classes of lipids with contrasting abundances identified in the plasma of rectal cancer patients.
m/z lipid Molecular formula lipid class Tendency
734.5685b Phosphatidylcholine (PC) (32:0) C40H80NO8P Glycerophosphocholine High
Phosphatidylethanolamine (PE) (35:0) Glycerophosphoethanolamine
756.554b PC (31:3) C42H78NO8P Glycerophosphocholine High
PE (34:3) Glycerophosphoethanolamine
792.5868b PC (P-38:5) C46H82NO7P Glycerophosphocholine High
PC (O-38:6)
820.5975b PC (P-40:5) C48H86NO7P Glycerophosphocholine High
PC (O-40:6)
478.3285a Lisophosphatidylcholine (LPC) (P-16:1) C24H48NO6P Glycerophosphocholine Low
496.3395a LPC (16:0) C24H50NO7P Glycerophosphocholine Low
506.3602a LPC (P-18:1) C26H52NO6P Glycerophosphocholine Low
504.3447a LPC (P-18:2) C26H50NO6P Glycerophosphocholine Low
524.371a LPC (18:0) C26H54NO7P Glycerophosphocholine Low
aIdentified by MS/MS fragmentation pattern.
bIdentified by exact mass only.
FigUre 3 | Important metabolite ions selected on the basis of variable 
importance in projection (VIP) score. The colored boxes on the right indicate 
relative bin integrals for healthy volunteers and rectal adenocarcinoma 
patients. VIP score is a weighted sum of squares of the PLS-DA loadings 
taking into account the amount of explained Y-variation in each dimension.
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reported previously. The functional role of changes in plasmanyl-
lipids in malignancy and metastasis are still poorly understood. 
It is unclear whether decreased levels of LPC plasmalogens are 
due to metabolic alteration in RAC or whether plasmalogens 
play an important role in the pathogenesis of RAC. High levels 
of PC (C30:0) and low levels of LPC (C18:0) were consistently 
related to higher risks of colorectal, breast, and prostate cancer, 
independently of background factors, such as age, BMI, dietary 
factors, or smoking status (38). In our study, the lipidomic sig-
nature was not correlated with demographic, anthropometric, 
clinical, or other lifestyle factors given that the number of subjects 
was insufficient for that to be done.
Our results show a relative reduction of MUFA (16:1), n − 6 
PUFA (20:4), and n − 3 PUFA (22:5 and 22:6) in plasma of early 
stages CRC patients. The observation of downregulation in FAs 
during cancer progression is in accordance with the previous 
studies of the hypermetabolic response and increased energy 
expenditure of cancer patients (39). Preliminary data reported 
a higher proportion of palmitic acid (18:0) and a lower eicosa-
pentaenoic (20:5 n − 3) proportion in the plasma PL fraction in 
the CRC patients than in the controls (40). A decrease of the 16:1 
n − 7/16:0 and 18:1 n − 9/18:0 ratios in colorectal tissue cancer 
has previously been observed, suggesting that change in FA ratios 
may be involved in the mechanism of CRC progression (41). 
Li et al. (42) reported that the reduction of oleamide and FAs (16:2, 
18:0, and 20:3) in serum achieved excellent diagnostic accuracy 
for differentiating early stages CRC patients from healthy controls. 
Although we were not able to identify differences in oxidative 
stress as estimated by 8-isoprostane levels between groups, we 
found that patients with RAC at stages III and IV have increased 
MDA values. The relation between the staging of the tumor 
and the increase in oxidative stress remains unclear. Previous 
research has shown that higher levels of oxidative stress markers 
are associated with an advanced state of cancer. Mendonça et al. 
(43) reported that higher MDA levels were found in the serum 
of patients with CRC at an advanced stage (III). Surinenaite et al. 
(44) also reported that in 65 patients serum MDA level was more 
elevated in advanced than early stage CRC. The serum MDA level 
was significantly decreased after surgical treatments compared to 
pre-surgical status. Gopčević et  al  (45) showed, however, that 
Japanese patients with CRC had high plasmatic levels of MDA 
at all stages compared to healthy individuals and there were no 
differences among the stages of the disease.
FigUre 4 | Malondialdehyde (a) and F2-isoprostane (B) levels of the healthy 
volunteers and rectal adenocarcinoma patients in the different cancer stages. 
*p < 0.05 compared to the healthy volunteers. #p < 0.05 compared to stage 
0; ANOVA followed by Tukey test. 1. Healthy volunteers, 2. Stages 0, 3. 
Stages I/II, 4. Stages III/IV.
TaBle 3 | Fatty acid (FA) composition (% total relative) of plasma total lipids in healthy volunteers (n = 18) and rectal adenocarcinoma (RAC) patients in the different 
cancer stages.
Fatty acids healthy volunteers (n = 18) stage 0a (n = 4) stages i/ii (n = 9) stages iii/iV (n = 10)
16:0 27.33 ± 4.37 26.27 ± 4.14 28.67 ± 2.75 28.96 ± 2.64
18:0 7.68 ± 1.44 8.11 ± 0.89 7.39 ± 0.96 7.48 ± 1.12
Σ SFA 35.01 ± 5.81 34.37 ± 5.03 36.07 ± 3.71 36.44 ± 3.76
16:1 n − 7 5.08 ± 0.79 4.21 ± 1.20 4.18 ± 1.45* (p = 0.0455) 4.25 ± 1.97
18:1 n − 9 20.06 ± 3.36 19.73 ± 4.28 20.25 ± 4.38 21.29 ± 1.92
Σ MUFA 25.14 ± 4.15 23.93 ± 5.48 24.23 ± 5.83 25.54 ± 3.90
18:2 n − 6 28.35 ± 5.66 27.08 ± 5.20 28.89 ± 5.97 25.82 ± 5.51
20:4 n − 6 (ARA) 5.12 ± 1.01 6.26 ± 2.42 4.33 ± 0.72* (p = 0.0472) 6.04 ± 2.50
Σ n − 6 PUFA 33.47 ± 6.67 33.33 ± 7.62 33.22 ± 6.69 31.85 ± 8.01
18:3 n − 3 1.35 ± 1.38 1.91 ± 1.36 0.97 ± 0.64 0.91 ± 0.59
20:5 n − 3 (EPA) 0.54 ± 0.42 0.60 ± 0.55 0.37 ± 0.23 0.30 ± 0.13
22:5 n − 3 (DPA) 0.33 ± 0.19 0.49 ± 0.43 0.17 ± 0.10* (p = 0.0268) 0.19 ± 0.06* (p = 0.0330)
22:6 n − 3 (DHA) 0.63 ± 0.28 0.79 ± 0.75 0.35 ± 0.12* (p = 0.0086) 0.49 ± 0.18
Σ n − 3 PUFA 2.85 ± 2.27 3.79 ± 3.08 1.86 ± 1.09 1.88 ± 0.97
Σ n − 6 PUFA/Σ n − 3 PUFA 11.7 ± 8.4 11.5 ± 7.4 17.8 ± 9.2 16.9 ± 9.5
*p < 0.05 compared to the healthy volunteers group (mean ± SD. Tukey test among three or more groups).
aPatients in the stage 0 group were excluded.
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid.
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cOnclUsiOn
Early stage RAC was characterized via MS lipid profiles by a reduced 
level of n  −  3 PUFA and LPC plasmalogen species. Our results 
pointed to this class as a disease biomarker and a better oxidative 
stress evaluator, since plasmalogen alterations can be observed 
in early stages of RAC. Plasmalogens might, therefore, work as 
biomarkers for diagnosis and also be an index for the surveillance 
of treatment effects. This was an explorative study and the observed 
associations need to be validated in a larger cohort that would make 
it feasible to adjust for more potential confounders in multivariate 
statistical tests, nevertheless, the results are indeed promising.
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